Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)

Recruiting now · Not applicable

Conditions studied: Acute Aortic Syndrome, Aortic Dissection Type a

In brief

Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.

Key facts

Study ID

NCT05339529

Run by

Nanjing Medical University

People needed

330

Starts

2022-07-01

Expected to finish

2025-12-31

Last updated by the study team

2024-12-12

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
• Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled.
• The patients' age between 18 \~90 years old.
• Agree to participate in the study and sign the informed consent.

You may not qualify if…

• Patients allergic to Thymosin α1;
• Lactating women and pregnant women;
• Patients with mental diseases, drug and alcohol dependence;
• Refuse to participate in this study and refuse to sign the informed consent.

Where it is running

• The First Affiliated Hospital of Bengbu Medical College — Bengbu, Anhui, China (enrolling)
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (enrolling)
• The First Affiliated Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)
• Nanjing First Hospital Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)
• Subei People's Hospital of Jiangsu Province — Yangzhou, Jiangsu, China (enrolling)
• Qilu Hospital of Shandong University — Jinan, Shandong, China (enrolling)
• West China Hospital of Sichuan University — Chengdu, Sichuan, China (enrolling)
• The Friendship Hospital of Yili Kazak Autonomous Prefecture — Kazak, Xinjiang, China (enrolling)
• The Seventh Affiliated Hospital of Xinjiang Medical University — Ürümqi, Xinjiang, China (enrolling)
• The First Affiliated Hospital of Kunming Medical University — Kunming, Yunnan, China (enrolling)
• Beijing Anzhen Hospital Capital Medical University — Beijing, China (enrolling)
• The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, China (enrolling)
• The Second Affiliated Hospital of Nanchang University — Nanchang, China (enrolling)
• Shanghai East Hospital Tongji University — Shanghai, China (enrolling)
• TEDA International Cardiovascular Hospital — Tianjin, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.